On the Frontlines of Non-Small Cell Lung Cancer

ReachMD

Stay current on the latest developments in the field with On the Frontlines of Non-Small Cell Lung Cancer, an exclusive podcast series featuring expert perspectives on emerging data, evolving treatment approaches, and other key considerations.

Episodes

  1. 02/09/2024

    Novel Immune Checkpoint Strategies in Non-Small Cell Lung Cancer Care

    Host: Jacob Sands, MD Guest: Aakesh Desai, MD, MPH According to research featured at the 2023 ASCO Annual Meeting, novel immune checkpoint targets have the potential to inform drug development and combination strategies to optimize the care of patients with non-small cell lung cancer. Tune in to hear Dr. Jacob Sands explore the key findings with Dr. Aakash Desai, an Assistant Professor of Medicine at the O’Neal Cancer Center at the University of Alabama at Birmingham.

  2. 12/28/2023

    NSCLC Care: Evaluating Durvalumab in the First-Line Setting

    Host: Jacob Sands, MD Guest: Liza Villaruz, MD According to a recent study, the immune checkpoint inhibitor durvalumab is not only considered safe, but it may also offer overall survival benefits for individuals with advanced or metastatic non-small cell lung cancer (NSCLC) and restricted performance status. Here to talk about this research are Dr. Jacob Sands and Dr. Liza Villaruz, Associate Professor of Medicine at the University of Pittsburgh School of Medicine.

  • 2 Episodes

About

Stay current on the latest developments in the field with On the Frontlines of Non-Small Cell Lung Cancer, an exclusive podcast series featuring expert perspectives on emerging data, evolving treatment approaches, and other key considerations.

Information